Context Therapeutics Inc.
- CNTX
- NASDAQ
- Biotechnology
- Cancer Immunotherapy (Bispecific Antibodies)
- Solid Tumor Therapeutics
$0.24
Today −2.30%Quote Oct 19, 2026, 08:00 PM UTC
−35.23%over the last month
Max drawdown −38.7%From 1-month high −38.7%3 months −62.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
15
Founded
2015
Market value
$21.9M
Quote Oct 19
Floor
$0.21
12.8% below price
Resistance
$0.26
8.3% above price
Price vs analyst targets
6 analysts
Lowest target
$4.50Highest target
$6.00
$4.50Highest target
$6.00
- Price $0.24
- Average target $5.25
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 2102% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CNTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free